Cargando…
PROTACs: great opportunities for academia and industry
Although many kinds of therapies are applied in the clinic, drug-resistance is a major and unavoidable problem. Another disturbing statistic is the limited number of drug targets, which are presently only 20–25% of all protein targets that are currently being studied. Moreover, the focus of current...
Autores principales: | Sun, Xiuyun, Gao, Hongying, Yang, Yiqing, He, Ming, Wu, Yue, Song, Yugang, Tong, Yan, Rao, Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927964/ https://www.ncbi.nlm.nih.gov/pubmed/31885879 http://dx.doi.org/10.1038/s41392-019-0101-6 |
Ejemplares similares
-
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
por: He, Ming, et al.
Publicado: (2022) -
Antiviral PROTACs: Opportunity borne with challenge
por: Liang, Jinsen, et al.
Publicado: (2023) -
PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020) -
FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice
por: Gao, Hongying, et al.
Publicado: (2020) -
PROTACs in gastrointestinal cancers
por: Chen, Yu, et al.
Publicado: (2022)